At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RNAZ TransCode Therapeutics Inc.
Trading 12-19 13:31:05 EST
3.83
-0.09
-2.30%
High3.95
Low3.78
Vol77.38K
Open3.86
D1 Closing3.92
Amplitude4.33%
Mkt Cap2.67M
Tradable Cap2.67M
Total Shares696.23K
T/O299.09K
T/O Rate11.12%
Tradable Shares696.10K
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), TransCode Therapeutics (RNAZ)
BRIEF-Transcode Therapeutics Announces Safety Review Committee Approval Of Opening Third Cohort And Preliminary Results From First Cohort In Phase 1 Ttx-Mc138 Trial
Transcode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results From First Cohort in Phase 1 Ttx-Mc138 Clinical Trial
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.